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ERare diseases’ management guidelines are produced with the primary aim of improving 
practice and standards of care for patients and may represent a useful framework for clinical 
practice. The EFNS/PNS (European Federation of Neurological Societies/Peripheral Nerve 
Society) guidelines for CIDP (chronic inflammatory demyelinating polyneuropathy) and 
MMN (multifocal motor neuropathy) were last published in 2010 (1, 2).  Enthusiasm of the 
audience for whom they are produced, arguably primarily non-sub-specialists, is however 
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largely unexplored. Compliance to these guidelines by neuromuscular and/or peripheral nerve 
specialists has not been investigated. 
In this issue of the journal, Rosier et al. describe the findings of their study specifically in 
relation to intravenous immunoglobulin (IVIg) treatment for these disorders (3). They aimed, 
through a survey, to evaluate French daily neurological practice in relation to the above-
mentioned published guidelines. They performed a retrospective observational study based 
on a pilot questionnaire validated by expert neurologists in the field. Four hundred and eleven 
neurologists were invited by e-mail to fill a general questionnaire and 4 patient case reports 
concerning recently seen or soon to be seen subjects. Of the 70 responders, 49 met pre-
defined criteria for inclusion in the analysis. A minority (26.6%) worked in neuromuscular 
reference centres (NRCs), coming from most (10 of the 13 existing) of the French NRCs, 
thereby offering an adequate global view of subspecialist practice. The authors mainly 
ascertained that initial treatment procedures for both CIDP and MMN conformed to existing 
guidelines. However, in greater detail, this essentially concerns the dose of 2g/kg used over 5 
days, the 4-weekly administration frequency with dose maintenance for the first 3 courses. In 
contrast, in relation to longer term therapy and guideline recommendations, some major and 
interesting discrepancies were observed, notably with non-NRC neurologist decreasing 
significantly more frequently the dose of IVIg than NRC neurologists (83% vs. 51%; p<0.05) 
and using immunosuppressants significantly less frequently (39% vs. 92%; p<0.05). 
Immunosuppressants were used for nearly 40% of cases by neurologists and although the 
details are not provided, it would be likely this practice was more common in NRCs. Dose 
reductions are recommended in the guidelines and implementation of this, appears from the 
reported findings of Rosier et al., less widespread amongst subspecialists. One may argue that 
NRCs see more severely affected subjects, although how this may justify sustained high dose 
therapy, presumably in circumstances of stability or progressive and possibly treatment-
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unrelated improvement, for over a quarter of subspecialists for the first 12 treatment courses, 
is somewhat mystifying. This is compounded by the two-fold and four-fold higher follow-up 
frequencies of CIDP and MMN patients respectively, in NRCs compared to the general 
neurology setting, which one would have expected making dose reduction decisions easier. 
On the other hand, the use of immunosuppressants, for which there is no current evidence 
base, is not recommended by the existing guidelines neither for CIDP nor for MMN. Despite 
this lack of justification, subspecialists appear to widely diverge from the recommendations 
in their practice, as opposed to generalists. Also, of note, and in relation to published data on 
the usually fixed frequency requirements particularly in CIDP (4, 5), all neurologists in 
contrast, more frequently altered treatment interval rather than dose (97% vs. 65% for CIDP 
and 98% vs. 51% for MMN).   
These findings in themselves clearly therefore suggest poor longer-term compliance to the 
guidelines, which importantly, but also perplexingly, appears to predominate in NRCs. That 
nearly a third of patients with CIDP and nearly half of those with MMN were referred by 
general neurologists to NRCs suggests that cases managed by subspecialists do not majorly 
differ in presentation or progression to those whose treatment remained in the hands of 
general neurologists. It is clear however that subsequent patient management differs 
significantly within as compared to outside NRCs, this in itself, irrespective of hypothetical 
underlying reasons, being inconsistent with the aim and objectives of guideline generation 
and dissemination. 
Our group conducted an international web-based audit on compliance to EFNS/PNS 
Guidelines on CIDP and MMN between 2012 and 2015 in 9 countries in total: Italy, 
Belgium, Serbia, Moldova, France, Hungary, Portugal, the United Kingdom and the state of 
Kerala in India. The main finding of our audit was the low response rate (globally 4.2% of all 
contacted potential participants). Nearly 60% of non-neuromuscular neurologists stated that 
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they used EFNS/PNS Guidelines to establish their therapeutic decision-making for CIDP and 
MMN. Nearly a sixth had however no knowledge of the Guidelines, the electrophysiological 
features being as expected, less commonly known than the clinical aspects. A large majority 
of neuromuscular neurologists preferred using EFNS/PNS criteria in clinical practice than 
any other criteria. Intravenous immunoglobulin dose reduction trials were, in contrast to 
Rosier et al.’s findings, reported as common practice for the majority of neuromuscular 
neurologists, for long-term patients. Although in lower proportions as compared to the French 
study, over 50% of neuromuscular neurologists declared feeling immunosuppression may be 
justified in CIDP, irrespective of the response to steroids, immunoglobulins or plasma 
exchange.  
Our analysis, through the poor responder rate from a large, similarly sampled, e-mailed 
invited, international neurological cohort, demonstrates a low level of interest in guidelines 
for rare diseases such as CIDP and MMN, particularly amongst general neurologists. 
Furthermore, a selection bias is likely to have occurred, as illustrated by the contrasting high 
level of guideline awareness in the surveyed sample. A similar selection bias is also likely in 
Rosier et al.’s study. Our results indicate that the surveyed sample was aware of the 
guidelines, but similarly to the French cohort, behaved variably in relation to the 
recommendations within them.  
Current EFNS/PNS guidelines represent very useful research tools as we have shown in a 
previous analysis (6). Awareness and compliance to these guidelines appear however, both 
from the data from Rosier et al. and from our international analysis, much more doubtful. In 
the French study, the poor long-term compliance amongst NRC neurologists enhances the 
concerns, indicating the need for greater coherence in the subspecialist arena, so as to 
improve newer versions and updates for all practitioners at large. New guidelines will be 
necessarily and rightly focused on the evidence base (7, 8). However, consideration of factors 
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impacting on dissemination and uptake will equally require careful consideration. It may be 
hoped this will ultimately allow the improvement and harmonisation of standards of care of 
all affected patients.  
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